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 Doosti A., P. Ghasemi-Dehkordi, M. Kargar, A.Sharifi (2015): Generation of 
divalent DNA vaccine based on p39 and shiga-like toxin 2 (stx2) gene- Genetika, Vol 47, 
No. 2, 499-507. 
The virulence factors such as shiga-like toxin (Stx) and immunogenic P39 
protein in Escherichia coli and Brucella melitensis are related to disease of digestive 
system in human worldwide. In the present study the stx2 and p39 genes were cloned 
into expression plasmid pEEF1D-FLAG (pcDNA 3.1+) as a divalent DNA vaccine 
candidate. The Enterohemorrhagic E. coli ATCC 3081 and smooth virulent B. melitensis 
strain M5 were obtained and cultured on specific media. Bacterial DNA was extracted 
from colonies and was used for p39 and stx2 genes amplification by PCR. The amplified 
products on 2% agarose gel electrophoresis were revealed 285 and 1220 bp fragments 
for stx2 and p39 genes, respectively. Each amplified genes were T/A cloned into pGEM-
T easy vector and pGEM-T-stx2 and pGEM-T-p39 were produced. The stx2 and p39 
genes were sub-cloned in linearized expression vector (pcDNA 3.1+) using HindIII, XhoI 
and XbaI restriction enzymes and pCDNA3-stx2-p39 was generated. This final construct 
was confirmed by PCR and enzymes digestion. The results were showed stx2 and p39 
genes were sub-cloned, successfully into pcDNA 3.1+ to generate pcDNA 3.1+-stx2-p39 
recombinant vector. According to these findings novel recombinant pcDNA 3.1+-stx2-
p39 construct that was produced in this study could be useful as DNA vaccine candidate 
in animal models against shiga-like toxin producing E. coli and virulence B. melitensis 
strains in future studies.   
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Bacterial infection special gastrointestinal bacteria such as Brucella melitensis (B. 
melitensis) and Escherichia coli (E. coli) are one of important concerns in digestion system, 
immune functions, and general health in the worldwide people. B. melitensis is an aerobic Gram 
negative coccobacillus bacterium from the Brucellaceae family and it is the most virulent 
Brucella spp. that is the causative agents of brucellosis in both humans and animals special in 
sheep and goats. This bacterium is facultative intracellular pathogens with short rods shape and 
contains three biovars (biovars 1, 2 and 3). In infected sheep and goats the symptoms are 
abortions, stillbirths, and the birth of weak offspring (DELVECCHIO et al., 2002). B. melitensis is a 
significant problem in under-developing countries and this pathogen is prevalent in southern and 
eastern edges of Mediterranean basin, particularly in Libya, Egypt, Tunisia, Syria, and in the 
Arabian Peninsula and Iran. The distribution of B. melitensis in Iran is varying in different areas 
of the country and biovar 1 is responsible for the disease in Isfahan, Khorasan, Guilan (north), 
Khoozestan (south), Yazd (central), and Kermanshah (west) provinces, whereas in Tehran and 
Azarbaijan the biovars 1, 2 and 3 are the responsible ones (ZOWGHI et al., 2008). The 39-
kilodalton protein (P39) is immunodominant protein and have important role in Brucella family 
infections (TIBOR et al., 1998). The p39 gene antigen of B. melitensis encoding periplasmic 
binding protein (PBP) and combined with CpG motifs as an adjuvant has been shown to elicit a 
Th1-type immune response (AL-MARIRI et al., 2001; BHATTACHARJEE et al., 2006). 
Shiga-like toxin 1 (stx1) and Shiga-like toxin 2 (stx2), also known as verotoxins 
produced by enterohemorrhagic E. coli (EHEC) and Shiga-like toxin-producing E. coli (STEC) 
such as E. coli O157:H7. These zoonotic food-borne pathogens are commonly associated with 
gastroenteritis, abdominal cramps and diarrhea which can be bloody, hemorrhagic colitis (HC), 
haemolytic-uremic syndrome (HUS) and in some cases death can occur. Stx genes in Shigella 
dysenteriae are located on the chromosome but these genes in E. coli are carried by lysogenic 
bacteriophages and can be acquired by horizontal gene transfer (O’BRIEN et al., 1992; MAURO and 
KOUDELKA, 2011). EHEC infections caused by E. coli O157 as well as non-O157 strains have 
global distribution but in Iran have varying rates in different years and studied groups 
(SALMANZADEH-AHRABI et al., 2005; ALIKHANI et al., 2007; BONYADIAN et al., 2010; JAFARI et 
al., 2012). Shiga toxins consist of two subunits include single A and B subunits. The B subunit of 
Stx1 and Stx2 binds to Gb3, which has been identified as the receptor for the Stx family 
(TAHAMTAN et al., 2010; SHARIFI-YAZDI et al., 2011; DOOSTI et al., 2011). The B subunit 
pentamer binds to globotriaosyl ceramide receptors on the cell membrane while A subunit acts as 
an RNA N-glycosidase enzyme, that catalyzes the release of an adenine at position 4324 in 28S 
rRNA of eukaryotic cells and inhibits protein synthesis. Furthermore, A and B subunits of stx1 
and stx2 in their nucleotide sequences and amino acid showed 57 to 60% and 55 to 57% 
homology, respectively (SATO et al., 2003; DOOSTI et al., 2011). 
In recent years, many vaccines are invented against bacterial pathogens like DNA 
vaccine. DNA vaccine is a kind of vaccines that induces immune responses by injecting it with 
genetically engineered DNA and could immunization against diseases caused by various 
pathogens such as bacteria, viruses, protozoa, and even use for tumors and illnesses with genetic 
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origins (LUO et al., 2006; SUN et al., 2012). DNA vaccines have many advantages include posing 
no risk of infection, induction of a long-lived immune response, elicit both humoral and cell 
mediated immunity, better stability than live attenuated vaccines, not required refrigeration, easy 
preparation, and cheap. The limitations of DNA vaccine are low but this type of vaccination 
would be restricted to pathogens with a distinctive protein immunogen, extended 
immunostimulation leads to chronic inflammation, and may increase slight risk of potentially 
disrupting normal cellular processes (LUO et al., 2006; SUN et al., 2012). For production of DNA 
vaccine virulence factors such as p39 and stx2 genes in B. melitensis and E. coli, respectively 
could be selected and these genes are important in pathogenicity and immune responses of these 
bacteria (DHANASHREE and SHRIKAR MALLYA, 2008; SUN et al., 2012). So, the present study was 
performed to generate of divalent DNA vaccine based on stx2 and p39 genes of E. coli and B. 
melitensis, respectively by cloning of these genes into expression vector pEEF1D-FLAG (pcDNA 
3.1+). 
 
MATERIALS AND METHODS 
Bacterial culture and plasmid preparation  
EHEC E. coli ATCC 3081 and smooth virulent B. melitensis strain M5 were maintained 
as frozen glycerol stocks were obtained from the Razi Institute (Karaj, Iran) and Microbiology 
laboratory of Islamic Azad University of Shahrekord Branch, respectively. B. melitensis were 
cultured into Brucella agar (Becton Dickinson Microbiological Systems, Franklin Lakes, NJ, 
USA) and E. coli ATCC 3081 were cultured on MacConkey agar and were incubated at 37°C in a 
5% CO2 atmosphere until OD 600 reaches 0.9-1. Also, pGEM-T easy vector and pcDNA 3.1+ 
(both Invitrogen, San Diego, CA) were used as cloning and expression vectors, respectively. E. 
coli strain Top10F' (Invitrogen, Carlsbad, USA) were cultured in 5 mL of Luria-Bertani (LB) 
broth at 37°C overnight and were used for cloning and plasmid preparation. 
 
Bacterial DNA extraction 
Bacterial genomic DNA was extracted from colonies of E. coli and B. melitensis using 
DNPTM Kit (CinnaGen, Iran) according to the manufacturer’s recommendation. The quality of 
total extracted DNA was measured by NanoDrop ND-1000 (PeqLab) at a wavelength of 260/280 




In the present study for amplification of stx2 and p39 genes specific oligonucleotide 
primers were designed according to the published sequences. The sequences of these primers 
included Stx2-F: 5'-ACGAAGCTTATGAAGAAGATGTTTATGGC-3' and Stx2-R: 5'-
ACGCTCGAGGTCATTATTAAACTGCAC-3' (accession number: KJ158456.1) containing 
HindIII and XhoI restriction sites, respectively and P39-F: 5'-
TAGTCTAGACGCCTGTTGCCAATGC-3' and P39-R: 5'-
GCGCTCGAGTTATTTTGCGGCTTCAAC-3' (accession number: JF918761.1) containing XbaI 
and XhoI restriction sites, respectively. For genes amplification the polymerase chain reaction 
(PCR) was performed using Thermal Cycler (Mastercycler Gradient, Eppendrof, Germany) in a 
final reaction volume of 50 µL in 0.5 mL tubes containing 1 µg of DNA sample, 1 µM of each 
forward and reverse primers, 2 mM MgCl2, 200 mM dNTPs, 5 µL of 10X PCR buffer, and 1 unit 
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of Taq DNA polymerase (all Fermentas, Germany). PCR temperature conditions involved an 
initial denaturation at 95°C for 5 minutes, followed by 32 cycles; denaturation at 94˚C for 1 min, 
annealing at 60˚C for 1 min, extension at 72˚C for 1 min, and a final extension at 72°C for 5 min 
was carried out at the end of the amplification program. The amplified products were detected in 
2% agarose gel electrophoresis and the gel was stained with ethidium bromide and photograph 
was obtained under UVIdoc gel documentation systems (Uvitec, UK). 
 
Cloning of stx and p39 genes and plasmid construction 
The amplified genes were purified from the gel using QIAquick Gel Extraction Kit 
(Qiagen, Inc.) according to manufacturer’s protocol. The extracted amplified products were T/A 
cloned in pGEM-T easy vector (Invitrogen, San Diego, CA) and the recombinant vectors were 
transformed into E. coli TOP10F' competent cells using calcium chloride solution and under heat 
shock (42°C) for 90s. Then, competent cells were cultured in LB agar media (Merck Co., 
Germany) containing Ampicillin antibiotic (100 µg/mL), IPTG (0.1 M) and Xgal (20 mg/mL) for 
screening of recombinant vectors at 37°C overnight. The white colonies were selected to 
preparation of matrix and were cultured again at 37°C overnight in LB broth media (containing 
Ampicillin antibiotic). The recombinant vectors were extracted from bacterial cells using Plasmid 
Mini Extraction Kit (BIONEER, South Korea) using manufacturer’s instructions and PCR and 
restriction enzymes analysis were used for confirmation of cloning. 
  
Sub-cloning of stx and p39 genes into expression vector pcDNA 3.1+ 
The 285 and 1220 bp fragments of stx2 and p39 genes were removed from recombinant 
pGEM-T easy vectors (pGEM-T-stx2 and pGEM-T-p39) by HindIII-XhoI and XbaI-XhoI double 
digestion, respectively and were sub-cloned in linearized pcDNA 3.1+ expression vector (5428 
bp) by these enzymes to produce pcDNA 3.1+-stx2 and pcDNA 3.1+-p39, respectively. Then, each 
recombinant linearized pcDNA 3.1+ using T4 ligase enzyme was ligated to generate the final 
recombinant expression vector (pcDNA 3.1+-stx2-p39). This construct was confirmed by PCR 
using specific oligonucleotide primers for stx2 and p39 genes and HindIII and XbaI restriction 
enzymes digestion.  
 
RESULTS  
The amplified stx2 and p39 genes on 2% agarose gel were revealed 285 and 1220 bp, 
fragments, respectively (Figure 1). These genes were T/A cloned using HindIII-XhoI and XbaI-
XhoI double digestion into pGEM-T easy vector (3015 bp) and pGEM-T-stx2 and pGEM-T-p39 
were produced, successfully. For confirmation of gene cloning pGEM-T-stx2 and pGEM-T-p39 
recombinant vectors were digested by HindIII, XhoI, and XhoI restriction enzymes. Then, pGEM-
T-stx2, pGEM-T-p39, and expression vector were digested and linearized with above restriction 
enzymes and stx2 and p39 genes were sub-cloned into pcDNA 3.1+ using T4 ligase enzyme and 
finally pcDNA 3.1+-stx2-p39 recombinant expression construct were generated, successfully. The 
results of enzyme digestion of pcDNA 3.1+-stx2-p39 construct on 2% agarose gel electrophoresis 
were revealed 1505 and 5428 bp for stx2-p39 consolidated segment and pcDNA 3.1+ vector 
(without inserted gene), respectively (Figure 2). 
 
 











Figure 1. The amplified stx2 and p39 genes of E. coli and B. melitensis on 2% agarose gel electrophoresis 
(Lane M is 1 kb DNA ladder (Fermentas, Germany), lanes 1 and 3 are amplified p39 (1220 bp) 












Figure 2. The enzymes digestion of pcDNA 3.1+-stx2-p39 recombinant construct (Lane M: 1 kb DNA 
marker (Fermentas, Germany), lanes 1 to 3 are digested pcDNA 3.1+-stx2-p39 construct to 
pcDNA 3.1+ vector (5428 bp) and stx2-p39 consolidated segment (1505 bp) by HindIII and XhoI 
restriction enzymes, and lane 4 is pcDNA 3.1+ without cloned gene) 
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DISCUSSION 
In recent years, generations of new vaccines to prevent bacterial pathogens are 
developed. In this study, a novel recombinant pcDNA 3.1+-stx2-p39 expression vector was 
generated as a divalent DNA vaccine candidate. In order to achieve this goal first stx2 and p39 
genes of E. coli and B. melitensis, respectively were amplified using specific oligonucleotide 
primers and were cloned successfully in pGEM-T easy vector. Then pGEM-T-stx2 and pGEM-T-
p39 recombinant plasmids using HindIII, XhoI and XbaI restriction enzymes and T4 ligase 
enzyme were sub-cloned in linearized pcDNA 3.1+ expression vector, successfully and pCDNA3-
stx2-p39 construct were generated. In recent decades, many studies performed to produce DNA 
vaccines and their applications against bacterial pathogens. KALUS et al. (1999) are used 
combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell 
immunity via T-cell costimulation and indicated that direct bearing on the design of vaccine 
clinical trials for infectious agents and/or tumor associated antigens (KALUS et al., 1999). AL-
MARIRI et al. (2001) evaluated the potential of P39 recombinant proteins and BFR with CpG 
ODN as adjuvant in inducing a Th1 response and the efficiency of these vaccines to protect 
BALB/c mice against an infectious B. abortus evaluated and concluded that mice protected at 8 
weeks but after BFR vaccination protection not observed. Their study showed that p39 factor that 
used in this study could stimulate the immune system as vaccine. LUO et al. (2006) constructed a 
DNA vaccine pcDNA3.1-Omp16 to investigate the potentiality of an Omp16-based DNA vaccine 
in protection against Brucella infection and concluded that Brucella DNA vaccine can elicit a 
higher cellular immune response and provide great protection for the host against Brucella 
infection. Their method same to the present work but we used stx2 and p39 genes of E. coli and B. 
melitensis to generate pCDNA3-stx2-p39 construct as a divalent DNA vaccine candidate. TU et 
al. (2015) in another study was cloned stx1 region (stx1a and stx1b) from E. coli O157:H7 into 
pET-32a with a single promoter, successfully, but in the present research, we cloned stx2 and p39 
genes to pcDNA 3.1+ expression vector. CHATTOPADHYAY et al. (2003) were cloned and 
expressed stx2 gene of STEC E. coli O157:H7 to pUC 18 and pUC 19 vectors. MEHREN et al. 
(2000) in a pilot study evaluated the dual gene recombinant Avipox vaccine containing both 
carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing 
adenocarcinomas and showed it is associated with the induction of a CEA specific T-cell 
response. CAPOZZO et al. (2003) were cloned B subunit of stx2 to the pCDNA 3+ as a DNA 
vaccine against E. coli producing Hemolytic-Uremic Syndrome in a murine model. Moreover, 
ACHESON et al. (1995) were cloned B subunit of stx2 gene to the pET9 for expression and 
purification of this gene and in study of BENTANCOR et al. (2009) the A and B subunits of stx2 of 
E. coli were cloned to pGEM-T easy vector successful and their method and cloning vector same 
to the present work. DOOSTI et al. (2009) were evaluated the immunogenicity and the protective 
efficacy of a divalent fusion DNA vaccine encoding both the B. melitensis Omp31 protein and 
P39 protein and who designated pCDNA3 recombinant vector as a divalent DNA vaccine. Their 
study was showed that intramuscular injection of this divalent DNA vaccine based on the omp31 
and p39 genes elicited cellular immune responses in Balb/c mice. In another study the heavy 
chain (HC) domain of Clostridium botulinum neurotoxin gene was cloned successful in E. coli 
using T/A cloning technique in PCR 8/GW/TOPO vector as a gene vaccine candidate (DOOSTI, 
2013). In addition, SUN et al. (2012) generated a divalent DNA vaccine based on Sia10 and 
OmpU and this vaccine induced cross protection against Streptococcus iniae and Vibrio 
anguillarum in Japanese flounder. DNA vaccines could activate both cellular and immune 
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response to protect the host from the pathogens. To summarize, the recombinant pCDNA3-stx2-
p39 DNA construct produced in the present study can be used as a DNA vaccine candidate 
against shiga-like toxin producing E. coli and virulence B. melitensis strains in future researches 
and the efficiency of this divalent DNA vaccine could evaluated in animal models.  
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U ovim ispitivanjima izvršeno je kloniranje stx2 i p39 gena u ekspresioni plazmid  pEEF1D-
FLAG (pcDNA 3.1+) kao kandidata za divalentnu vakcinu.  Dobijeni su Enterohemorrhagic E. 
coli ATCC 3081 i vrsta umereno virulentnog soja  B. melitensis i gajeni na specifičnim 
podlogama. Izolovana je bakterijska DNK iz  kolonija i korišćena za umnožavanje p39 i stx2 gena 
amplificijom primenom PCR reakcije. Amplifikovani produkti su separisani na 2% agaroznom 
gelu i dobijeno je 285 odnosno 1220 fragmenata za stx2 i p39 gene. Svaki amplifikovani A/T gen  
kloniran je  u  pGEM-T vektor i pGEM-T-stx2 i pGEM-T-p39 su proizvedeni. Stx2 i  p39 geni su 
subklonirani  u linearizovan eksresioni vektor (pcDNA 3.1+) korišćenjem HindIII, XhoI i XbaI 
restrikcionih enzima i generisan je CDNA3-stx2-p39. Finalni konstrukt je potvrđen reakcijom 
PCR i digestijom.  Rezultati pokazuju da su reakcije bile uspešne. Prema dobijenim rezultatima 
dobijen je novi recombinantni pcDNA 3.1+-stx2-p39 konstrukt koji može da bude koristan kao 
kandidat DNA vakcine kod animalnih sistema prema ispitivanim sojevima patogena.  
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